Erste Group Bank Forecasts Sandoz Group FY2026 Earnings

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) – Equities researchers at Erste Group Bank issued their FY2026 earnings per share (EPS) estimates for Sandoz Group in a research report issued on Thursday, August 27th. Erste Group Bank analyst H. Engel expects that the company will post earnings of $4.10 per share for the year. Erste Group Bank has a “Strong-Buy” rating on the stock. The consensus estimate for Sandoz Group’s current full-year earnings is $4.11 per share. Erste Group Bank also issued estimates for Sandoz Group’s FY2027 earnings at $4.61 EPS.

Separately, Barclays raised Sandoz Group from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Four investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Strong Buy”.

Sandoz Group Stock Down 1.2%

Shares of OTCMKTS SDZNY opened at $84.11 on Tuesday. The stock’s 50-day simple moving average is $85.82 and its two-hundred day simple moving average is $83.78. Sandoz Group has a twelve month low of $55.42 and a twelve month high of $94.15. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.77 and a current ratio of 1.18.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.